FTC Enforcement Hangs Over Memory Product Firm After Overlooking NAD Review
This article was originally published in The Rose Sheet
Executive Summary
KNH Online did not respond to NAD's request for information supporting claims for its Adderin supplement, including the statement "clinically proven to sky-rocket concentration by 312%" and a customer testimonial that "it started working within minutes of taking it … I experienced a mental clarity that I’d never felt before."
You may also be interested in...
Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications
Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.
GAO Memory Supplement Review Recalls FDA's Regulatory Challenges
GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.
Supplement Claims Targeting Elderly, Weight Conscious Top FTC Priorities
Dubious supplement ad claims that have driven FTC enforcement in the sector for some time likely will continue as three commission seats are filled, says advertising practices official Richard Cleland.